journal article·2024-10Open access

Type I collagen-targeted liposome delivery of Serca2a modulates myocardium calcium homeostasis and reduces cardiac fibrosis induced by myocardial infarction

Wanshi Chen, Lingjuan Liu, Ming Tang, Jiajin Li, Wenjing Yuan, Dan Yin, Yang Cao, Jie Tian

Abstract

Fibrotic scarring and impaired myocardial calcium homeostasis serve as the two main factors in the pathology of heart failure following myocardial infarction (MI), leading to poor prognosis and death in patients. Serca2a is a target of interest in gene therapy for MI-induced heart failure via the regulation of intracellular calcium homeostasis and, subsequently, enhancing myocardial contractility. A recent study also reported that Serca2a ameliorates pulmonary fibrosis by blocking nuclear factor kB (NF-kB)/interleukin-6 (IL-6)-induced (SMAD)/TGF-β signaling activation, while the effect in MI-induced myocardial fibrosis remains to be addressed. Here, we loaded Serca2a plasmids into type 1 collagen-targeting nanoparticles to synthesize the GKWHCTTKFPHHYCLY-Serca2a-Liposome (GSL-NPs) for targeted treatment of myocardial infarction. We showed that GSL-NPs were effectively targeted in the scar area in MI-induced mice within tail-vein delivery for 48 h. Treatment with GSL-NPs improved cardiac functions and shrank fibrotic scars after MI in mice by up-regulating Serca2a. In cardiac fibroblasts, GSL-NPs alleviated hypoxia-induced fibrotic progression partly by inhibiting NF-kB activation. Furthermore, treatment with GSL-NPs protected cardiomyocyte calcium homeostasis and enhanced myocardial contractility during hypoxia. Together, we demonstrate that type I collagen-targeted liposome delivery of Serca2a may benefit patients with myocardial infarction by inhibiting fibrotic scarring as well as modulation of calcium homeostasis.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Cardiac Fibrosis and Remodeling · Tissue Engineering and Regenerative Medicine · Electrospun Nanofibers in Biomedical Applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (61)

Show source-provided references
1. Heart failure after myocardial infarction: incidence and predictors10.1002/ehf2.13144 ↗
2. Heart failure with reduced ejection fraction
3. Ibanez · Eur. Heart J. · 2017 · 39 · 11910.1093/eurheartj/ehx393 ↗
4. Fundamental mechanisms of regulated cell death and implications for heart disease10.1152/physrev.00022.2018 ↗
5. The biological basis for cardiac repair after myocardial infarction: from inflammation to fibrosis10.1161/CIRCRESAHA.116.303577 ↗
6. Calcium dysregulation in heart diseases: targeting calcium channels to achieve a correct calcium homeostasis10.1016/j.phrs.2022.106119 ↗
7. Low-dose empagliflozin improves systolic heart function after myocardial infarction in rats: regulation of MMP9, NHE1, and SERCA2a10.3390/ijms22115437 ↗
8. Biventricular pacing cardiac contractility modulation improves cardiac contractile function via upregulating SERCA2 and miR-133 in a rabbit model of congestive heart failure10.1159/000358705 ↗
9. LncRNA ZFAS1 as a SERCA2a inhibitor to cause intracellular Ca(2+) overload and contractile dysfunction in a mouse model of myocardial infarction10.1161/CIRCRESAHA.117.312117 ↗
10. In vivo effects of nitrosyl hydrogen on cardiac function and sarcoplasmic reticulum calcium pump (SERCA2a) in rats with heart failure after myocardial infarction10.21037/cdt-20-201 ↗
11. Reduced SERCA2a converts sub-lethal myocardial injury to infarction and affects postischemic functional recovery10.1016/j.yjmcc.2008.10.026 ↗
12. USP25 ameliorates pathological cardiac hypertrophy by stabilizing SERCA2a in cardiomyocytes10.1161/CIRCRESAHA.122.321849 ↗
13. Luteolin modulates SERCA2a via Sp1 upregulation to attenuate myocardial ischemia/reperfusion injury in mice
14. Lentiviral vector-mediated SERCA2 gene transfer protects against heart failure and left ventricular remodeling after myocardial infarction in rats10.1038/mt.2008.61 ↗
15. AAV1.SERCA2a gene therapy reverses pulmonary fibrosis by blocking the STAT3/FOXM1 pathway and promoting the SNON/SKI Axis10.1016/j.ymthe.2019.11.027 ↗
16. Fibroblast-specific TGF-β-Smad2/3 signaling underlies cardiac fibrosis10.1172/JCI94753 ↗
17. EphrinB2 regulates cardiac fibrosis through modulating the interaction of Stat3 and TGF-β/Smad3 signaling10.1161/CIRCRESAHA.117.311045 ↗
18. Signaling pathways and targeted therapy for myocardial infarction10.1038/s41392-022-00925-z ↗
19. The function and significance of SERA2a in congestive heart failure: an analysis of gene therapy trials
20. Effect of the peptides Relaxin, Neuregulin, Ghrelin and Glucagon-like peptide-1, on cardiomyocyte factors involved in the molecular mechanisms leading to diastolic dysfunction and/or heart failure with preserved ejection fraction10.1016/j.peptides.2018.05.009 ↗
21. Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial10.1016/S0140-6736(16)00082-9 ↗
22. A non-invasive nanoparticles for multimodal imaging of ischemic myocardium in rats10.1186/s12951-021-00822-7 ↗
23. Photoacoustic imaging of myocardial infarction region using non-invasive fibrin-targeted nanoparticles in a rat myocardial ischemia-reperfusion model10.2147/IJN.S293736 ↗
24. Collagen-targeted MRI contrast agent for molecular imaging of fibrosis10.1002/anie.200700700 ↗
25. Advances in antibody phage display technology10.1016/j.drudis.2022.05.002 ↗
26. Stiffness of aortic arch and carotid arteries increases in ApoE-knockout mice with high-fat diet: evidence from echocardiography
27. Downregulation of G protein-coupled receptor kinase 4 protects against kidney ischemia-reperfusion injury10.1016/j.kint.2022.12.023 ↗
28. Dedifferentiation, proliferation, and redifferentiation of adult mammalian cardiomyocytes after ischemic injury10.1161/CIRCULATIONAHA.116.024307 ↗
29. Intranuclear cardiac troponin I plays a functional role in regulating Atp2a2 expression in cardiomyocytes10.1016/j.gendis.2021.04.007 ↗
30. ZBP1 protects against mtDNA-induced myocardial inflammation in failing hearts10.1161/CIRCRESAHA.122.322227 ↗
31. Kaempferol-3-O-rutinoside exerts cardioprotective effects through NF-κB/NLRP3/Caspase-1 pathway in ventricular remodeling after acute myocardial infarction10.1111/jfbc.14305 ↗
32. LRG1 promotes hypoxia-induced cardiomyocyte apoptosis and autophagy by regulating hypoxia-inducible factor-1α10.1080/21655979.2021.1988368 ↗
33. EIF4A3-Induced circ-BNIP3 aggravated hypoxia-induced injury of H9c2 cells by targeting miR-27a-3p/BNIP310.1016/j.omtn.2019.11.017 ↗
34. Transcription factor JDP2 activates PDE4B to participate in hypoxia/reoxygenation-induced H9c2 cell injury10.3892/etm.2022.11270 ↗
35. Heart targeted nanoliposomal/nanoparticles drug delivery: an updated review10.1016/j.biopha.2016.12.009 ↗
36. Nanosystems in cardiovascular medicine: advancements, applications, and future perspectives10.3390/pharmaceutics15071935 ↗
37. Reactive oxygen species-based nanomaterials for the treatment of myocardial ischemia reperfusion injuries
38. Notoginsenoside R1-loaded mesoporous silica nanoparticles targeting the site of injury through inflammatory cells improves heart repair after myocardial infarction10.1016/j.redox.2022.102384 ↗
39. Inhalation of peptide-loaded nanoparticles improves heart failure10.1126/scitranslmed.aan6205 ↗
40. Phage display technology as a powerful platform for antibody drug discovery10.3390/v13020178 ↗
41. Applications of the phage display technology in molecular biology, biotechnology and medicine
42. Advances in functional and molecular MRI technologies in chronic liver diseases10.1016/j.jhep.2020.06.020 ↗
43. Ischemic cardiomyopathy and heart failure after acute myocardial infarction10.1007/s11886-022-01766-6 ↗
44. Cardiac-specific deletion of voltage dependent anion channel 2 leads to dilated cardiomyopathy by altering calcium homeostasis10.1038/s41467-021-24869-0 ↗
45. Increased SERCA2a sub-cellular heterogeneity in right-ventricular heart failure inhibits excitation-contraction coupling and modulates arrhythmogenic dynamics10.1098/rstb.2021.0317 ↗
46. SERCA2a protein levels are unaltered in human heart failure10.1161/CIRCULATIONAHA.123.064513 ↗
47. SERCA2a agonist effects on cardiac performance during exercise in heart failure with preserved ejection fraction10.1016/j.jchf.2023.02.006 ↗
48. Complex relationship between cardiac fibroblasts and cardiomyocytes in Health and disease10.1161/JAHA.120.019338 ↗
49. Reversible differentiation of myofibroblasts by MyoD10.1016/j.yexcr.2011.03.016 ↗
50. Myocyte-fibroblast communication in cardiac fibrosis and arrhythmias: mechanisms and model systems10.1016/j.yjmcc.2016.03.005 ↗
51. Mir-30d regulates cardiac remodeling by intracellular and paracrine signaling10.1161/CIRCRESAHA.120.317244 ↗
52. Extracellular vesicles in cardiovascular diseases10.1038/s41420-020-00305-y ↗
53. Microneedle patch loaded with exosomes containing MicroRNA-29b prevents cardiac fibrosis after myocardial infarction
54. Left ventricular remodelling post-myocardial infarction: pathophysiology, imaging, and novel therapies10.1093/eurheartj/ehac223 ↗
55. Defining the timeline of periostin upregulation in cardiac fibrosis following acute myocardial infarction in mice10.1038/s41598-022-26035-y ↗
56. Direct reprogramming improves cardiac function and reverses fibrosis in chronic myocardial infarction10.1161/CIRCULATIONAHA.121.058655 ↗
57. Qiliqiangxin attenuates cardiac remodeling via inhibition of TGF-β1/smad3 and NF-κB signaling pathways in a rat model of myocardial infarction10.1159/000487871 ↗
58. Fibroblast-specific deletion of interleukin-1 receptor-1 reduces adverse cardiac remodeling following myocardial infarction10.1172/jci.insight.125074 ↗
59. Foxm1 is a critical driver of TGF-β-induced EndMT in endothelial cells through Smad2/3 and binds to the Snail promoter10.1002/jcp.27583 ↗
60. C1q/TNF-Related protein 9 inhibits coxsackievirus B3-induced injury in cardiomyocytes through NF-κB and TGF-β1/smad2/3 by modulating THBS110.1155/2020/2540687 ↗
61. Resveratrol attenuates pressure overload-induced cardiac fibrosis and diastolic dysfunction via PTEN/AKT/Smad2/3 and NF-κB signaling pathways10.1002/mnfr.201900418 ↗